Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this March/April 2022 editionm the focus is oncost variation and mis-estimation in clinical trial budgets.
Facing limited resources and increasing operating and workforce-related costs across expanding drug development portfolios, sponsor companies are seeking ways to reign in clinical trial costs. At the same time, protocol designs continue to become more complex, resulting in higher levels of inefficiency, greater patient recruitment and retention challenges, and unplanned and unbudgeted disruptions.
Based on the results of a recent working group study, this Tufts CSDD Impact Report examines clinical trial budgets and offers insight into the factors driving commonly observed variation and cost.
The full report is available for purchase here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.